Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Sep 30, 2026, 3:46 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 27 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Haemophilia A Without Inhibitors Clear all
Recruiting Phase 3 Interventional

A Clinical Study to Evaluate the Effects of NXT007 Compared to Factor VIII Prophylaxis in Participants With Hemophilia A

NCT07416526
View directory record Official record
Conditions
Hemophilia A
Interventions
NXT007, Human Coagulation Factor VIII
Combination Product · Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
12 Years and older
Enrollment
138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
2
States / cities
Aurora, Colorado • Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Sep 30, 2026, 3:46 AM EDT
Completed Phase 2 Interventional Results available

A Trial Evaluating Efficacy and Safety of Prophylactic Administration of Concizumab in Patients With Severe Haemophilia A Without Inhibitors

NCT03196297
View directory record Official record
Conditions
Haemostasis, Haemophilia A
Interventions
Concizumab, Turoctocog alfa
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older · Male only
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
5
States / cities
Los Angeles, California • Indianapolis, Indiana • Oklahoma City, Oklahoma + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 16, 2021 · Synced Sep 30, 2026, 3:46 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

A Research Study Investigating Mim8 in People With Haemophilia A

NCT04204408
View directory record Official record
Conditions
Healthy Volunteers, Haemophilia A With or Without Inhibitors
Interventions
NNC0365-3769 (Mim8), Placebo (Mim8)
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
12 Years and older · Male only
Enrollment
275 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
15
States / cities
Phoenix, Arizona • Los Angeles, California • Atlanta, Georgia + 12 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2025 · Synced Sep 30, 2026, 3:46 AM EDT
Completed Phase 3 Interventional Results available

Study of the Efficacy and Safety PF-06741086 in Adult and Teenage Participants With Severe Hemophilia A or Moderately Severe to Severe Hemophilia B

NCT03938792
View directory record Official record
Conditions
Hemophilia A, Hemophilia B
Interventions
PF-06741086
Drug
Lead sponsor
Pfizer
Industry
Eligibility
12 Years to 74 Years · Male only
Enrollment
188 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
4
States / cities
Tampa, Florida • Iowa City, Iowa • New Hyde Park, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2026 · Synced Sep 30, 2026, 3:46 AM EDT
Completed Phase 3 Interventional

A Research Study Looking at Mim8 in Children With Haemophilia A With or Without Inhibitors

NCT05306418
View directory record Official record
Conditions
Haemophilia A With or Without Inhibitors
Interventions
Mim8
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
1 Year to 11 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
9
States / cities
Los Angeles, California • Aurora, Colorado • Tampa, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2025 · Synced Sep 30, 2026, 3:46 AM EDT
Completed Phase 3 Interventional

A Research Study Looking at How Safe it is to Switch From Emicizumab to Mim8 in People With Haemophilia A (FRONTIER 5)

NCT05878938
View directory record Official record
Conditions
Haemophilia A, Haemophilia A With Inhibitors
Interventions
NNC0365-3769 (Mim8) PPX
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
12 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
13
States / cities
Los Angeles, California • Sacramento, California • Aurora, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Dec 8, 2025 · Synced Sep 30, 2026, 3:46 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Safety & Efficacy of Encapsulated Allogeneic FVIII Cell Therapy in Haemophilia A

NCT04541628
View directory record Official record
Conditions
Hemophilia A
Interventions
SIG-001
Combination Product
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older · Male only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
3
States / cities
Indianapolis, Indiana • Boston, Massachusetts • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 4, 2024 · Synced Sep 30, 2026, 3:46 AM EDT
Completed Phase 3 Interventional Results available

A Study of Fitusiran (ALN-AT3SC) in Severe Hemophilia A and B Patients Without Inhibitors

NCT03417245
View directory record Official record
Conditions
Hemophilia A, Hemophilia B
Interventions
fitusiran, factor concentrates
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
12 Years and older · Male only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
8
States / cities
Little Rock, Arkansas • Gainesville, Florida • Tampa, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2022 · Synced Sep 30, 2026, 3:46 AM EDT
Active, not recruiting Phase 3 Interventional Results available

A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Subcutaneous Emicizumab in Participants From Birth to 12 Months of Age With Hemophilia A Without Inhibitors

NCT04431726
View directory record Official record
Conditions
Severe Hemophilia A
Interventions
Emicizumab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
0 Months to 12 Months
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2030
U.S. locations
6
States / cities
Phoenix, Arizona • Los Angeles, California • Aurora, Colorado + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Sep 30, 2026, 3:46 AM EDT
Terminated Phase 3 Interventional Results available

The Hemophilia Inhibitor Prevention Trial

NCT04303559
View directory record Official record
Conditions
Hemophilia A Without Inhibitor
Interventions
Eloctate Injectable Product, Emicizumab Injection [Hemlibra]
Drug
Lead sponsor
Margaret Ragni
Other
Eligibility
4 Months to 4 Years · Male only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
3
States / cities
Little Rock, Arkansas • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 11, 2023 · Synced Sep 30, 2026, 3:46 AM EDT
Recruiting Phase 3 Interventional

Open-Label Extension Study of Marstacimab in Hemophilia Participants With or Without Inhibitors

NCT05145127
View directory record Official record
Conditions
Hemophilia A, Hemophilia B
Interventions
PF-06741086
Drug
Lead sponsor
Pfizer
Industry
Eligibility
1 Year to 74 Years · Male only
Enrollment
245 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2030
U.S. locations
4
States / cities
Iowa City, Iowa • New Hyde Park, New York • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Sep 30, 2026, 3:46 AM EDT
Completed No phase listed Observational

A Study Following People With Haemophilia A and B, With or Without Inhibitors, When on Usual Treatment (Explorer™6)

NCT03741881
View directory record Official record
Conditions
Haemophilia A, Haemophilia A With Inhibitors, Haemophilia B, Haemophilia B With Inhibitors
Interventions
No treatment given
Other
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
12 Years and older · Male only
Enrollment
231 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
29
States / cities
Los Angeles, California • Sacramento, California • Aurora, Colorado + 24 more
Source: ClinicalTrials.gov public record
Updated Nov 23, 2021 · Synced Sep 30, 2026, 3:46 AM EDT
Completed Phase 1 Interventional Results available

Phase 1 Safety, Pharmacokinetics And Pharmacodynamics Study Of Recombinant Factor VIIa Variant (813d) In Adult Subjects With Hemophilia

NCT01439971
View directory record Official record
Conditions
Hemophilia A
Interventions
PF-05280602
Biological
Lead sponsor
Catalyst Biosciences
Industry
Eligibility
18 Years to 64 Years · Male only
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
9
States / cities
San Diego, California • New Haven, Connecticut • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated May 12, 2017 · Synced Sep 30, 2026, 3:46 AM EDT
Completed No phase listed Observational

ATHN 7: Hemophilia Natural History Study

NCT03619863
View directory record Official record
Conditions
Hemophilia A With Inhibitor, Haemophilia A Without Inhibitor, Hemophilia B With Inhibitor, Haemophilia B Without Inhibitor
Interventions
Not listed
Lead sponsor
American Thrombosis and Hemostasis Network
Network
Eligibility
Not listed
Enrollment
395 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
29
States / cities
Phoenix, Arizona • Los Angeles, California • San Diego, California + 23 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2025 · Synced Sep 30, 2026, 3:46 AM EDT
Active, not recruiting Phase 4 Interventional

A Study to Evaluate Overall Health, Physical Activity, and Joint Outcomes in Participants With Severe or Moderate Hemophilia A Without Factor VIII Inhibitors on Emicizumab Prophylaxis

NCT05181618
View directory record Official record
Conditions
Severe Hemophilia A, Moderate Hemophilia A
Interventions
Emicizumab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
13 Years to 69 Years
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
3
States / cities
Los Angeles, California • Miami, Florida • Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Sep 30, 2026, 3:46 AM EDT
Active, not recruiting Phase 3 Interventional Results available

Research Study to Look at How Well the Drug Concizumab Works in Your Body if You Have Haemophilia Without Inhibitors

NCT04082429
View directory record Official record
Conditions
Haemophilia A Without Inhibitors, Haemophilia B Without Inhibitors
Interventions
Concizumab
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
12 Years and older · Male only
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
12
States / cities
Los Angeles, California • Orange, California • Augusta, Georgia + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Sep 30, 2026, 3:46 AM EDT
Terminated Phase 4 Interventional Results available

Study of Emicizumab Prophylaxis in Participants With Hemophilia A With or Without Inhibitors Undergoing Minor Surgical Procedures

NCT03361137
View directory record Official record
Conditions
Hemophilia A
Interventions
Emicizumab
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
Not listed
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
8
States / cities
Los Angeles, California • Palo Alto, California • Gainesville, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 1, 2021 · Synced Sep 30, 2026, 3:46 AM EDT
Completed Phase 3 Interventional Results available

A Clinical Trial to Evaluate Prophylactic Emicizumab Versus no Prophylaxis in Hemophilia A Participants Without Inhibitors

NCT02847637
View directory record Official record
Conditions
Hemophilia A
Interventions
Emicizumab, Factor VIII (FVIII)
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
12 Years and older
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
8
States / cities
Santa Monica, California • Washington D.C., District of Columbia • Gainesville, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 16, 2022 · Synced Sep 30, 2026, 3:46 AM EDT
Recruiting Phase 4 Interventional

A Study to Test a Medicine (Fitusiran) for Preventing Bleeds in People With Severe Hemophilia Who Previously Received Preventive Treatment With Emicizumab

NCT06145373
View directory record Official record
Conditions
Hemophilia A
Interventions
Fitusiran (SAR439774), Clotting factor concentrates (CFC) or bypassing agents (BPA), Antithrombin concentrate (ATIIIC), Emicizumab
Drug · Biological
Lead sponsor
Sanofi
Industry
Eligibility
12 Years and older · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
2
States / cities
Los Angeles, California • Flowood, Mississippi
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Sep 30, 2026, 3:46 AM EDT
Recruiting Phase 3 Interventional

A Clinical Trial of Study Medicine (Marstacimab) in Pediatric Patients With Hemophilia A or Hemophilia B

NCT05611801
View directory record Official record
Conditions
Hemophilia A, Hemophilia B
Interventions
marstacimab
Drug
Lead sponsor
Pfizer
Industry
Eligibility
1 Year to 17 Years · Male only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Sep 30, 2026, 3:46 AM EDT
Active, not recruiting Phase 3 Interventional

A Research Study on How Well Concizumab Works for You if You Have Haemophilia A or B With or Without Inhibitors

NCT05135559
View directory record Official record
Conditions
Haemophilia A and B With and Without Inhibitors
Interventions
Concizumab
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
Not listed
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
19
States / cities
San Diego, California • Aurora, Colorado • Orlando, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Sep 30, 2026, 3:46 AM EDT
Completed No phase listed Observational

ATHN 8: Previously Untreated Patients (PUPs) Matter Study

NCT03818529
View directory record Official record
Conditions
Hemophilia, Hemophilia A, Hemophilia B, Hemophilia A With Inhibitor, Hemophilia B With Inhibitor, Haemophilia B Without Inhibitor, Haemophilia A Without Inhibitor, Haemophilia
Interventions
Not listed
Lead sponsor
American Thrombosis and Hemostasis Network
Network
Eligibility
0 Years to 13 Years
Enrollment
237 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
27
States / cities
Phoenix, Arizona • Madera, California • San Diego, California + 24 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2023 · Synced Sep 30, 2026, 3:46 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of Emicizumab in Participants With Mild or Moderate Hemophilia A Without FVIII Inhibitors

NCT04158648
View directory record Official record
Conditions
Mild Hereditary Factor VIII Deficiency Disease Without Inhibitor, Moderate Hereditary Factor VIII Deficiency Disease Without Inhibitor, Hemophilia A
Interventions
Emicizumab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
Not listed
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
5
States / cities
Los Angeles, California • Atlanta, Georgia • Indianapolis, Indiana + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Sep 30, 2026, 3:46 AM EDT
Active, not recruiting Phase 3 Interventional

A Research Study Looking at Long-term Treatment With Mim8 in People With Haemophilia A

NCT05685238
View directory record Official record
Conditions
Haemophilia A, Haemophilia A With Inhibitors
Interventions
Mim8
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
Not listed
Enrollment
451 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
15
States / cities
Los Angeles, California • Aurora, Colorado • Miami, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Sep 30, 2026, 3:46 AM EDT